Why the study?
Translating multimodal biosensing data into clinical practice for CVD monitoring is hindered by a trustworthiness gap. Current architectures lack robustness to sensor noise, produce poorly calibrated confidence estimates, ignore physiological causality, and fail to align with clinician workflows.
Population
Literature on multimodal biosensing in cardiovascular health across PubMed, IEEE Xplore, Scopus, and arXiv (2018-2026)
Design
Systematic narrative review
Answers are grounded in this paper and cite their sources.
Trust gaps in multimodal biosensing warrant clinical caution; leaves open reliable translation pending causal modeling and validation.
Cardiovascular disease (CVD) monitoring increasingly relies on multimodal biosensors, including electrocardiography (ECG), photoplethysmography (PPG), and advanced imaging systems. While deep learning has enhanced the analytical capacity of these biosensors, the translation of multimodal sensing data into clinical practice is hindered by a trustworthiness gap. Current biosensing architectures often lack robustness to sensor noise, produce poorly calibrated confidence estimates, ignore physiological causality, and fail to align with clinician workflows. Employing a systematic narrative review methodology across PubMed, IEEE Xplore, Scopus, and arXiv (2018–2026), this paper synthesizes the literature around six interconnected challenge areas in biosensor data integration: uncertainty quantification and conflict resolution; handling missing and misaligned modalities; knowledge-guided representation and fusion; causal and evidential reasoning; robust clinical evaluation; and human-centered integration. We propose a taxonomy of fusion strategies based on their trustworthiness properties and identify critical limitations in current methodologies, such as the tendency of black-box transformers to exploit spurious correlations in sensor data and the brittleness of early fusion under distribution shift. Furthermore, we outline a comprehensive research roadmap emphasizing causal disentanglement, federated multimodal learning, and interactive clinician-AI loops. By bridging algorithmic innovation with biosensor reliability, this review provides a blueprint for developing reliable, interpretable, and equitable multimodal biosensing systems. However, we emphasize that while these technical directions are promising, prospective clinical validation, standardized regulatory benchmarks, and equitable dataset curation remain essential prerequisites before these systems can be considered clinically validated solutions capable of transforming cardiovascular care.
No takes yet. Share an insight, caveat, or question.
Akram et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: